BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front‐line therapy for high‐risk patients with diffuse large cell lymphoma
In two consecutive and unselected cohorts of diffuse large cell lymphoma (DLCL) patients with advanced stage disease (IIB or bulk or more) and aged < 60 years, we compared a standard (MACOP‐B for 12 weeks, 60 patients) versus a high‐dose chemotherapy programme (8 weeks of MACOP‐B plus one or two cycles of intensification with mitoxanthrone, dexamethasone, high‐dose Ara‐C, and finally BEAM chemotherapy with autologous haemopoietic progenitor cell transplantation, 61 patients). 41 patients (68%) in the standard group and 51 (84%) in the high‐dose chemotherapy group, achieved a complete remission (CR) or an uncertain complete remission (CRu) (P = 0.0491). With a median follow‐up time of 28 months for the high‐dose group and 63.5 months for the standard group, the actuarial estimate of event‐free survival (EFS) at 2 years demonstrates a significant benefit (70% v 50%, P = 0.03) for patients treated with the intensive regimen. The analysis of subgroups of patients showed that only high‐risk patients (two or three risk factors) benefitted from the high‐dose chemotherapy programme. Nevertheless, the overall survival does not show a significant difference between the two treatment modalities. The treatment‐related morbidity was similar and the mortality rate was 8% in the standard (MACOP‐B) group and 3% in the high‐dose chemotherapy programme. In conclusion, our results show that high‐dose chemotherapy and autologous stem cell transplantation is a safe procedure which should be considered for the front‐line treatment of non‐Hodgkin lymphoma patients with poor prognostic features.